With regard to brain tumors, both B-RAF (dabrafenib and vemurafenib) and MEK inhibitors (trametinib and cobimetinib) seem to present an optimal pharmacokinetic profile with good therapeutic concentration in the CNS and are currently used in the treatment of some glial tumors, such as pleomorphic xanthoastrocytoma, ganglioglioma, and BRAF V600E–mutant glioblastoma with systemic metastases [13,15]. The gene discussed is BRAF; the disease is ganglioglioma.